Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Biological therapies, such as hydroxychloroquine, may
stimulate the immune system in different ways and stop cancer cells from growing. It is not
yet known whether imatinib mesylate is more effective when given with or without
hydroxychloroquine in treating patients with chronic myeloid leukemia.
PURPOSE: This randomized phase II trial is studying the side effects of giving imatinib
mesylate with or without hydroxychloroquine and to see how well it works in treating patients
with chronic myeloid leukemia.